We first assessed the effects of the allosteric SHP2 inhibitor SHP099 [13] and/or the pan-PI3K inhibitor CLR457 [20] on the 4T1 mouse mammary carcinoma cell line and on a panel of human breast cancer cell lines. This evidence concerns the gene PTPN11 and breast carcinoma.